{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:28:34Z","timestamp":1787909314181,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01032-y","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:20:25Z","timestamp":1756718425000},"page":"833-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful kidney transplantation using eltrombopag in a patient with MYH9-related disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Aya","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-4766","authenticated-orcid":false,"given":"Yoko","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kunishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-8482","authenticated-orcid":false,"given":"Kenichiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"1032_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s100380170007","volume":"46","author":"S Kunishima","year":"2001","unstructured":"Kunishima S, Matsushita T, Kojima T, et al. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet. 2001;46:722\u20139.","journal-title":"J Hum Genet"},{"issue":"3","key":"1032_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.md.0000076006.64510.5c","volume":"82","author":"M Seri","year":"2003","unstructured":"Seri M, Pecci A, Bari FD, et al. MYH9-related disease: May-hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82(3):203\u201315.","journal-title":"Medicine (Baltimore)"},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ki.2010.21","volume":"78","author":"T Sekine","year":"2010","unstructured":"Sekine T, Konno M, Sasaki S, et al. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int. 2010;78:207\u201314.","journal-title":"Kidney Int"},{"key":"1032_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/MOH.0b013e32833c069c","volume":"17","author":"S Kunishima","year":"2010","unstructured":"Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol. 2010;17:405\u201310.","journal-title":"Curr Opin Hematol"},{"key":"1032_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s10157-023-02404-3","volume":"28","author":"Y Shirai","year":"2024","unstructured":"Shirai Y, Miura K, Hamada R, et al. A nationwide survey of MYH9-related disease in Japan. Clin Exp Nephrol. 2024;28:40\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1032_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1399-0012.2010.01274.x","volume":"24","author":"M Ogura","year":"2010","unstructured":"Ogura M, Kikuchi E, Kaito H, et al. ABO-incompatible renal transplantation in Epstein syndrome. Clin Transpl. 2010;24:31\u20134.","journal-title":"Clin Transpl"},{"key":"1032_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.transproceed.2013.11.144","volume":"46","author":"SY Min","year":"2014","unstructured":"Min SY, Ahn HJ, Park WS, et al. Successful renal transplantation in MYH9-related disorder with severe macrothrombocytopenia: first report in Korea. Transpl Proc. 2014;46:654\u20136.","journal-title":"Transpl Proc"},{"key":"1032_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2215\/CJN.00700117","volume":"13","author":"R Zhang","year":"2018","unstructured":"Zhang R. Donor-specifc antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2018;13:182\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1032_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12185-013-1401-1","volume":"98","author":"S Katsutani","year":"2013","unstructured":"Katsutani S, Tomiyama Y, Kimura A, et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013;98:323\u201330.","journal-title":"Int J Hematol"},{"key":"1032_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1182\/blood.V116.21.2533.2533","volume":"116","author":"A Pecci","year":"2010","unstructured":"Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood. 2010;116:583\u20137.","journal-title":"Blood"},{"key":"1032_CR11","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1002\/ajh.25500","volume":"94","author":"C Zaninetti","year":"2019","unstructured":"Zaninetti C, Barozzi S, Bozzi V, et al. Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia. Am J Hematol. 2019;94:E199-201.","journal-title":"Am J Hematol"},{"key":"1032_CR12","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1542\/peds.2012-3807","volume":"132","author":"R Favier","year":"2013","unstructured":"Favier R, Feriel J, Favier M, et al. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics. 2013;132:e793\u20135.","journal-title":"Pediatrics"},{"key":"1032_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1213\/XAA.0000000000000621","volume":"10","author":"R Favier","year":"2018","unstructured":"Favier R, De Carne C, Elefant E, Lapusneanu R, Gkalea V, Rigouzzo A. Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9-related disease: a case report. AA Pract. 2018;10:10\u20132.","journal-title":"AA Pract"},{"key":"1032_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.anl.2020.09.008","volume":"49","author":"A Mori","year":"2022","unstructured":"Mori A, Takeda H, Kobayashi M, et al. Successful cochlear implantation in a patient with Epstein syndrome during long-term follow-up. Auris Nasus Larynx. 2022;49:308\u201312.","journal-title":"Auris Nasus Larynx"},{"key":"1032_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13730-023-00786-7","volume":"12","author":"M Nakamura","year":"2023","unstructured":"Nakamura M, Miura K, Shirai Y, et al. Successful administration of eltrombopag in preparation for peritoneal dialysis catheter placement in a girl with MYH9-related disease. CEN Case Rep. 2023;12:419\u201322.","journal-title":"CEN Case Rep"},{"issue":"4","key":"1032_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/nep.13253","volume":"24","author":"J Hashimoto","year":"2019","unstructured":"Hashimoto J, Hamasaki Y, Takahashi Y, et al. Management of patients with severe Epstein syndrome: review of four patients who received living-donor renal transplantation. Nephrology. 2019;24(4):450\u20135.","journal-title":"Nephrology"},{"key":"1032_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31534","volume":"72","author":"J Carter","year":"2025","unstructured":"Carter J, Shanmugalingam T, Lafond S, et al. Successful use of TPO-receptor agonist eltrombopag to correct thrombocytopenia for unrelated-donor renal transplant in an adolescent with MYH9-related disease. Pediatr Blood Cancer. 2025;72:e31534.","journal-title":"Pediatr Blood Cancer"},{"key":"1032_CR18","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130:2527\u201336.","journal-title":"Blood"},{"key":"1032_CR19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.transproceed.2024.05.029","volume":"56","author":"Y Ishiyama","year":"2024","unstructured":"Ishiyama Y, Yagisawa T, Ichioka M, et al. Comparative analysis of real-world efficacy and safety of hypoxia-inducible factor prolyl-hydroxylase inhibitors in kidney transplant recipients versus nontransplant individuals: a single-center study. Transplant Proc. 2024;56:1300\u20137.","journal-title":"Transplant Proc"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01032-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:12:45Z","timestamp":1762845165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01032-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01032-y","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflict of interest. This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent for genetic testing and off-label use of eltrombopag was obtained from the patient and her guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}